secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-09-30T10:09:56+00:00
Accession:  0001193125-26-408224
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Sagimet: denifanstat hits 56.7% IGA success at 52 weeks in Ascletis Phase 3 OLE; US AURORA screening starts October
--------------------------------------------------------------------------------

- 52-week Phase 3 OLE (ASC40-304) in China: 56.7% treatment success across 240 patients (57.8% denifanstat/denifanstat vs 55.6% placebo/denifanstat).
- Mean reductions vs ASC40-303 baseline: total lesion count -71.8%, inflammatory lesions -76.9%, non-inflammatory lesions -66.9%.
- Denifanstat 50 mg was generally well-tolerated up to 52 weeks: no permanent discontinuations or drug-related serious AEs; dry skin 7.1%, dry eye 5.9%.
- Sagimet's US AURORA Phase 3 screening begins October 2026: ~800 patients (450 aged 12-17), randomized 2:1 to denifanstat 50 mg or placebo over 12 weeks.
- Sagimet terminated the ATM prospectus supplement under its Aug 14, 2025 Sales Agreement with Leerink Partners; no further share sales unless a new prospectus is filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/0001193125-26-408224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-408224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer